LINC01756

Across TCGA pan-cancer cohorts, LINC01756 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LINC01756’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC01756 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01756 is over-expressed in tumor, although a few such as PAAD show the opposite, repressed pattern.

BRCA, LIHC, and PAAD are the cancer types where LINC01756 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01756 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.040	.019	4	view →
LIHC	All	All	+0.023	.003	3	view →
PAAD	Female	All	−0.050	.037	2	view →
COAD	All	All	+0.009	.026	2	view →
KIRC	All	All	+0.008	.008	2	view →
STAD	All	II,III,IV	+0.033	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

LINC01756–BRCA

Open the BRCA breakdown →